Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Reexamination Certificate
2000-12-14
2004-04-13
Page, Thurman K. (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
C424S445000, C424S447000, C424S448000, C424S449000, C424S543000, C424S646000, C424S725000, C424S900000, C424S900000, C424S900000
Reexamination Certificate
active
06719997
ABSTRACT:
TECHNICAL FIELD
This invention relates generally to the topical and transdermal administration of pharmacologically active agents, and more particularly relates to methods, drug delivery systems and pharmaceutical compositions for transdermal administration of pharmologically active amines.
BACKGROUND
The delivery of drugs through the skin provides many advantages; primarily, such a means of delivery is a comfortable, convenient and noninvasive way of administering drugs. The variable rates of absorption and metabolism encountered in oral treatment are avoided, and other inherent inconveniences—e.g., gastrointestinal irritation and the like—are eliminated as well. Transdermal drug delivery also makes possible a high degree of control over blood concentrations of any particular drug. Side effects typically associated with oral administration may be substantially avoided, and the likelihood of both patient acceptance and patient compliance is significantly improved.
Skin is a structurally complex, relatively thick membrane. Molecules moving from the environment into and through intact skin must first penetrate the stratum corneum and any material on its surface. They must then penetrate the viable epidermis, the papillary dermis, and the capillary walls into the blood stream or lymph channels. To be so absorbed, molecules must overcome a different resistance to penetration in each type of tissue. Transport across the skin membrane is thus a complex phenomenon. However, it is the cells of the stratum corneum which present the primary barrier to absorption of topical compositions or transdermally administered drugs. The stratum corneum is a thin layer of dense, highly keratinized cells approximately 10-15 microns thick over most of the body. It is believed to be the high degree of keratinization within these cells as well as their dense packing which creates in most cases a substantially impermeable barrier to drug penetration. With many drugs, the rate of permeation through the skin is extremely low without the use of some means to enhance the permeability of the skin.
In order to increase the rate at which a drug penetrates through the skin, then, various approaches have been followed, each of which involves the use of either a chemical penetration enhancer or a physical penetration enhancer. Physical enhancement of skin permeation includes, for example, electrophoretic techniques such as iontophoresis. The use of ultrasound (or “phonophoresis”) as a physical penetration enhancer has also been researched. Chemical enhancers are compounds that are administered along with the drug (or in some cases the skin may be pretreated with a chemical enhancer) in order to increase the permeability of the stratum corneum, and thereby provide for enhanced penetration of the drug through the skin. Ideally, such chemical penetration enhancers (or “permeation enhancers,” as the compounds are referred to herein) are compounds that are innocuous and serve merely to facilitate diffusion of the drug through the stratum corneum.
Various compounds for enhancing the permeability of skin are known in the art and described in the pertinent texts and literature. Compounds that have been used to enhance skin permeability include: the sulfoxides dimethylsulfoxide (DMSO) and decylmethylsulfoxide (C
10
MSO); ethers such as diethylene glycol monoethyl ether (available commercially as Transcutol®) and diethylene glycol monomethyl ether; surfactants such as sodium laurate, sodium lauryl sulfate, cetyltrimethylammonium bromide, benzalkonium chloride, Poloxamer (231, 182, 184), Tween (20, 40, 60, 80) and lecithin (U.S. Pat. No. 4,783,450); the 1-substituted azacycloheptan-2-ones, particularly 1-n-dodecylcyclazacycloheptan-2-one (available under the trademark Azone® from Nelson Research & Development Co., Irvine, Calif.; see U.S. Pat. Nos. 3,989,816, 4,316,893, 4,405,616 and 4,557,934); alcohols such as ethanol, propanol, octanol, benzyl alcohol, and the like; fatty acids such as lauric acid, oleic acid and valeric acid; fatty acid esters such as isopropyl myristate, isopropyl palmitate, methylpropionate, and ethyl oleate; polyols and esters thereof such as propylene glycol, ethylene glycol, glycerol, butanediol, polyethylene glycol, and polyethylene glycol monolaurate (PEGML; see, e.g., U.S. Pat. No. 4,568,343); amides and other nitrogenous compounds such as urea, dimethylacetamide (DMA), dimethylformamide (DMF), 2-pyrrolidone, 1-methyl-2-pyrrolidone, ethanolamine, diethanolamine and triethanolamine; terpenes; alkanones; and organic acids, particularly salicylic acid and salicylates, citric acid and succinic acid.
Percutaneous Penetration Enhancers
, eds. Smith et al. (CRC Press, 1995) provides an excellent overview of the field and further background information on a number of chemical and physical enhancers.
Although many chemical permeation enhancers are known, there is an ongoing need for enhancers that are highly effective in increasing the rate at which a drug permeates the skin, do not result in skin damage, irritation, sensitization, or the like, and can be used to effect transdermal delivery of even high molecular weight drugs such as steroid drugs. It has now been discovered that hydroxide-releasing agents are highly effective permeation enhancers, even when used without coenhancers, provide all of the aforementioned advantages relative to known permeation enhancers. Furthermore, in contrast to conventional enhancers, transdermal administration of drugs with hydroxide-releasing agents as permeation enhancers, employed at the appropriate levels, does not result in systemic toxicity.
The present invention is directed to the transdermal administration of pharmacologically active amines. Many amine drugs exhibit low transdermal flux rate, particularly when the drug is in the form of an acid addition salt. For example, racemic phenylpropanolamine (i.e., (±)-phenylpropanolamine, a mixture of (−)-norephedrine and (+)-norephedrine) is only 16 &mgr;g/cm
2
/hr. See, for example, U.S. Pat. No. 4,818,541. Scopolamine, a well known anti-emetic agent and anti-nauseant, also exhibits relatively low transdermal flux, necessitating application to a very specific skin area. Numerous other amine drugs are also known to be problematic in this regard.
Furthermore, many amine drugs are available commercially only in the form of an acid addition salt. When the agents are to be administered transdermally, it is generally necessary to convert the acid addition salt to the free amine base before incorporation into a transdermal delivery device. The method of the '541 patent is representative of such a procedure, in that the patent requires neutralization of phenylpropanolamine hydrochloride (i.e., conversion to the free base), the commercially available form of the drug, before incorporation into a transdermal drug delivery system.
Accordingly, there is a need in the art for a way to transdermally administer a pharmacologically active amine at a transdermal flux rate that is high enough to ensure that physiologically effective blood levels of the drug are obtained. It would also be desirable to provide a transdermal system wherein it is unnecessary to convert an acid addition salt to the base form of the drug prior to patch manufacture. It has now been discovered that use of hydroxide-releasing agents as permeation enhancers fulfills both of the aforementioned functions.
SUMMARY OF THE INVENTION
It is thus a primary object of the invention to address the above-described need in the art by providing drug delivery systems, pharmaceutical formulations and methods for the transdermal administration of pharmacologically active amines.
It is another object of the invention to provide a method for treating conditions, disorders or diseases that are responsive to administration of a pharmacologically active amine by transdermally administering the amine in conjunction with a hydroxide-releasing agent as a permeation enhancer.
It is still another object of the invention to provide a method for transdermally admini
Hsu Tsung-Min
Luo Eric C.
Macy Russell
Dermatrends, Inc.
Eberle Shelley P.
George Konata M.
Page Thurman K.
Reed Dianne E.
LandOfFree
Transdermal administration of pharmacologically active... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transdermal administration of pharmacologically active..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal administration of pharmacologically active... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3193275